Prelude Therapeutics announces clinical collaboration with Merck

Prelude Therapeutics (PRLD) announced that it has entered into a clinical trial collaboration and supply agreement with Merck (MRK). Under the terms of the Agreement, the Phase 2 clinical study will evaluate PRT3789, the Company’s investigational, highly selective, first-in-class SMARCA2 degrader in combination with KEYTRUDA Merck’s anti-PD-1 therapy, in patients with SMARCA4-mutated cancers. “We are excited for this opportunity to work together with Merck on this study combining our novel, highly selective SMARCA2 degrader with KEYTRUDA,” stated Prelude’s President and Chief Medical Officer Jane Huang, M.D. “Through this collaboration of potentially complementary mechanisms, we may have the potential to positively impact clinical outcomes in patients harboring a SMARCA4 mutation, who have previously been known to have limited treatment options.”